These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 30221089)

  • 21. Administration of low-dose resveratrol attenuated hepatic inflammation and lipid accumulation in high cholesterol-fructose diet-induced rat model of nonalcoholic fatty liver disease.
    Chang CC; Chang CY; Lin PC; Huang JP; Chen KH; Yen TH; Hung LM
    Chin J Physiol; 2020; 63(4):149-155. PubMed ID: 32859881
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hyperoside attenuates non-alcoholic fatty liver disease in rats via cholesterol metabolism and bile acid metabolism.
    Wang S; Sheng F; Zou L; Xiao J; Li P
    J Adv Res; 2021 Dec; 34():109-122. PubMed ID: 35024184
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Resveratrol improves hepatic steatosis by inducing autophagy through the cAMP signaling pathway.
    Zhang Y; Chen ML; Zhou Y; Yi L; Gao YX; Ran L; Chen SH; Zhang T; Zhou X; Zou D; Wu B; Wu Y; Chang H; Zhu JD; Zhang QY; Mi MT
    Mol Nutr Food Res; 2015 Aug; 59(8):1443-57. PubMed ID: 25943029
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Monascin and ankaflavin act as natural AMPK activators with PPARα agonist activity to down-regulate nonalcoholic steatohepatitis in high-fat diet-fed C57BL/6 mice.
    Hsu WH; Chen TH; Lee BH; Hsu YW; Pan TM
    Food Chem Toxicol; 2014 Feb; 64():94-103. PubMed ID: 24275089
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Emodin palliates high-fat diet-induced nonalcoholic fatty liver disease in mice via activating the farnesoid X receptor pathway.
    Shen C; Pan Z; Wu S; Zheng M; Zhong C; Xin X; Lan S; Zhu Z; Liu M; Wu H; Huang Q; Zhang J; Liu Z; Si Y; Tu H; Deng Z; Yu Y; Liu H; Zhong Y; Guo J; Cai J; Xian S
    J Ethnopharmacol; 2021 Oct; 279():114340. PubMed ID: 34171397
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Resveratrol administration or SIRT1 overexpression does not increase LXR signaling and macrophage-to-feces reverse cholesterol transport in vivo.
    Escolà-Gil JC; Julve J; Llaverias G; Urpi-Sarda M; Silvennoinen R; Lee-Rueckert M; Andres-Lacueva C; Blanco-Vaca F
    Transl Res; 2013 Feb; 161(2):110-7. PubMed ID: 23146569
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Protective effect of ursodeoxycholic acid, resveratrol, and N-acetylcysteine on nonalcoholic fatty liver disease in rats.
    Ali MH; Messiha BA; Abdel-Latif HA
    Pharm Biol; 2016 Jul; 54(7):1198-208. PubMed ID: 26134756
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Resveratrol Reduced Liver Damage After Liver Resection in a Rat Model by Upregulating Sirtuin 1 (SIRT1) and Inhibiting the Acetylation of High Mobility Group Box 1 (HMGB1).
    Yu S; Zhou X; Xiang H; Wang S; Cui Z; Zhou J
    Med Sci Monit; 2019 May; 25():3212-3220. PubMed ID: 31041919
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Resveratrol reverses the programmed high-susceptibility to non-alcoholic fatty liver disease by targeting the hepatic SIRT1-SREBP1c pathway in prenatal ethanol-exposed rat offspring.
    Shen L; Xie L; Chen L; Liu L; Shi X; Wang X; Chen D; Wang H; Quan S; Wang Z
    J Toxicol Sci; 2021; 46(9):413-423. PubMed ID: 34470993
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bile Acid Nuclear Receptor Farnesoid X Receptor: Therapeutic Target for Nonalcoholic Fatty Liver Disease.
    Kim SG; Kim BK; Kim K; Fang S
    Endocrinol Metab (Seoul); 2016 Dec; 31(4):500-504. PubMed ID: 28029021
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Improvement effect and mechanism of ethanol extract from Citri Reticulatae Pericarpium on triglyceride in hyperlipidemia model rat].
    DU YZ; Su J; Yan MQ; Chen SH; Lyu GY; Yu JJ
    Zhongguo Zhong Yao Za Zhi; 2021 Jan; 46(1):190-195. PubMed ID: 33645070
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Resveratrol does not benefit patients with nonalcoholic fatty liver disease.
    Chachay VS; Macdonald GA; Martin JH; Whitehead JP; O'Moore-Sullivan TM; Lee P; Franklin M; Klein K; Taylor PJ; Ferguson M; Coombes JS; Thomas GP; Cowin GJ; Kirkpatrick CM; Prins JB; Hickman IJ
    Clin Gastroenterol Hepatol; 2014 Dec; 12(12):2092-103.e1-6. PubMed ID: 24582567
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Novel Role of SIRT1/ FGF-21 in Taurine Protection Against Cafeteria Diet-Induced Steatohepatitis in Rats.
    Abd Elwahab AH; Ramadan BK; Schaalan MF; Tolba AM
    Cell Physiol Biochem; 2017; 43(2):644-659. PubMed ID: 28942443
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activation of farnesoid X receptor attenuates hepatic injury in a murine model of alcoholic liver disease.
    Wu W; Zhu B; Peng X; Zhou M; Jia D; Gu J
    Biochem Biophys Res Commun; 2014 Jan; 443(1):68-73. PubMed ID: 24269813
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Regulatory effect of a Chinese herbal medicine formula on non-alcoholic fatty liver disease.
    Yang JM; Sun Y; Wang M; Zhang XL; Zhang SJ; Gao YS; Chen L; Wu MY; Zhou L; Zhou YM; Wang Y; Zheng FJ; Li YH
    World J Gastroenterol; 2019 Sep; 25(34):5105-5119. PubMed ID: 31558860
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Therapeutic effects of insulin-sensitizing drugs on nonalcoholic fatty liver disease: experiment with rats].
    Zhang DM; Zhang GY; Wang T; Zhong HJ; Chen WK
    Zhonghua Yi Xue Za Zhi; 2006 May; 86(18):1279-83. PubMed ID: 16796890
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of Sleeve Gastrectomy on Nonalcoholic Fatty Liver Disease in an Obese Rat Model.
    Watanabe K; Ohta M; Takayama H; Tada K; Shitomi Y; Kawasaki T; Kawano Y; Endo Y; Iwashita Y; Inomata M
    Obes Surg; 2018 Jun; 28(6):1532-1539. PubMed ID: 29280057
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Electroacupuncture Attenuates Liver Inflammation in Nonalcoholic Fatty Liver Disease Rats.
    Ma B; Li P; An H; Song Z
    Inflammation; 2020 Dec; 43(6):2372-2378. PubMed ID: 32737656
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease.
    Faghihzadeh F; Adibi P; Rafiei R; Hekmatdoost A
    Nutr Res; 2014 Oct; 34(10):837-43. PubMed ID: 25311610
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Effect of Nrf2 and related factors on the progression of nonalcoholic steatohepatitis].
    Cai YQ; Zhang LZ; Wang DJ; Chen FM; Chen ZY; Zhu KY; Li JS; Yan MX
    Zhongguo Ying Yong Sheng Li Xue Za Zhi; 2014 Sep; 30(5):465-70. PubMed ID: 25571645
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.